NewsBenzingaC4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting Benzinga 2026.09.25 11:02 (GMT+0) Open on Benzinga Other news Palantir Stock: AI In Production While Everyone Else Is Still Piloting (NASDAQ:PLTR) American Express Releases Intent Intelligence Framework to Advance Common Standards for Agentic Commerce Trump Defends Russia Sanctions Pause, Says Zelensky’s Refinery Strikes Are Hurting US Diesel Markets: ‘I Want This War End’ Trader closes high-leverage BTC and ETH longs, losing $4.34 million this round Japanese edition of CZ's autobiography "Freedom of Money" launches, all proceeds to be donated to charity YC Co-founder Paul Graham: Paywalled Content Will Be "Invisible" to AI, Equivalent to Nonexistent
American Express Releases Intent Intelligence Framework to Advance Common Standards for Agentic Commerce
Trump Defends Russia Sanctions Pause, Says Zelensky’s Refinery Strikes Are Hurting US Diesel Markets: ‘I Want This War End’
Japanese edition of CZ's autobiography "Freedom of Money" launches, all proceeds to be donated to charity
